Search
IN8BIO, Inc.
INABAdd to Watchlist
1.080USD
+0.010+0.93%
Close 09-18 16:00（ET）
10.44MMarket Cap
LossP/E TTM
More Details of IN8BIO, Inc. Company
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.
IN8BIO, Inc. Profile
Ticker SymbolINAB
Company nameIN8bio Inc
IPO dateNov 12, 2020
CEOHo (William T)
Number of employees18
Security typeOrdinary Share
Fiscal year-endNov 12
AddressEmpire State Building
CityNEW YORK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code10118
Phone16466006438
Websitehttps://www.in8bio.com
Ticker SymbolINAB
IPO dateNov 12, 2020
CEOHo (William T)
Company Executives of IN8BIO, Inc.
Name
Name/Position
Position
Shareholding
Change
Mr. Peter C. Brandt
Mr. Peter C. Brandt
Independent Director
Independent Director
98.69K
-0.00%
Ms. Luba Greenwood
Ms. Luba Greenwood
Independent Director
Independent Director
7.83K
+96.66%
Dr. Corinne Epperly
Dr. Corinne Epperly
Independent Director
Independent Director
2.73K
--
Mr. William T. Ho
Mr. William T. Ho
Co-Founder, Director
Co-Founder, Director
--
--
Dr. Lawrence S. Lamb, Ph.D.
Dr. Lawrence S. Lamb, Ph.D.
Co-Founder, Executive Vice President, Chief Scientific Officer
Co-Founder, Executive Vice President, Chief Scientific Officer
--
--
Mr. Patrick Mccall, CPA
Mr. Patrick Mccall, CPA
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
--
--
Mr. Alan S. Roemer
Mr. Alan S. Roemer
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Kate Rochlin, Ph.D.
Dr. Kate Rochlin, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
--
--
Ms. Emily Wang Fairbairn
Ms. Emily Wang Fairbairn
Independent Director
Independent Director
--
--
Dr. Jeremy R. Graff, Ph.D.
Dr. Jeremy R. Graff, Ph.D.
Interim Independent Chairman of the Board
Interim Independent Chairman of the Board
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Peter C. Brandt
Mr. Peter C. Brandt
Independent Director
Independent Director
98.69K
-0.00%
Ms. Luba Greenwood
Ms. Luba Greenwood
Independent Director
Independent Director
7.83K
+96.66%
Dr. Corinne Epperly
Dr. Corinne Epperly
Independent Director
Independent Director
2.73K
--
Mr. William T. Ho
Mr. William T. Ho
Co-Founder, Director
Co-Founder, Director
--
--
Dr. Lawrence S. Lamb, Ph.D.
Dr. Lawrence S. Lamb, Ph.D.
Co-Founder, Executive Vice President, Chief Scientific Officer
Co-Founder, Executive Vice President, Chief Scientific Officer
--
--
Mr. Patrick Mccall, CPA
Mr. Patrick Mccall, CPA
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
--
--
FAQs
Who are the top five shareholders of IN8BIO, Inc.?
The top five shareholders of IN8BIO, Inc. are: Mr. Peter C. Brandt
How many institutions hold shares of IN8BIO, Inc. (INAB)?
As of 2026Q1, 58 institutions hold shares of IN8BIO, Inc., with a combined market value of approximately 3.23M, accounting for 32.78% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 1290322.00.